Author Correction: Tissue mechanics promote IDH1-dependent HIF1α–tenascin C feedback to regulate glioblastoma aggression (Nature Cell Biology, (2016), 18, 12, (1336-1345), 10.1038/ncb3429);Tissue mechanics promote IDH1-dependent HIF1α-tenascin C feedback to regulate glioblastoma aggression

Nature Cell Biology

Volumn 18, Issue 12, 2016, Pages 1336-1345

  Miroshnikova, Yekaterina A ^a   Mouw, Janna K ^a   Barnes, J Matthew ^a   Pickup, Michael W ^a   Lakins, Johnathan N ^a   Kim, Youngmi ^b   Lobo, Khadjia ^a   Persson, Anders I ^a,c   Reis, Gerald F ^a   McKnigh, Tracy R ^a   Holland, Eric C ^b   Phillips, Joanna J ^a,c   Weaver, Valerie M ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOCITRATE DEHYDROGENASE 1; MICRORNA; MICRORNA 203; TENASCIN; UNCLASSIFIED DRUG; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; MIRN203 MICRORNA, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING ORGAN SYSTEMS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEEDBACK SYSTEM; FEMALE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GLIOBLASTOMA; HIF1A GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IDH1 GENE; MECHANOTRANSDUCTION; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MECHANICS; TNC GENE; TUMOR MICROENVIRONMENT; BRAIN TUMOR; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGICAL FEEDBACK; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

BRAIN NEOPLASMS; CELL LINE, TUMOR; EXTRACELLULAR MATRIX; FEEDBACK, PHYSIOLOGICAL; FLUORESCENT ANTIBODY TECHNIQUE; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOCITRATE DEHYDROGENASE; MECHANOTRANSDUCTION, CELLULAR; MICRORNAS; MUTATION; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION; TENASCIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84994662715     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/s41556-023-01126-8     Document Type: Erratum

References (46)

1. Brat D. J, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481-2498 (2015).
2. Yan H, et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
3. Van den Bent M. J, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-Term follow-up of EORTC brain tumor group study 26951. J. Clin. Oncol. 31, 344-350 (2013).
4. Cairncross G, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-Term results of RTOG 9402. J. Clin. Oncol. 31, 337-343 (2013).
5. Losman J.-A. J. A, & Kaelin W. G. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 27, 836-852 (2013).
6. Zhao S, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1. Science 324, 261-265 (2009).
7. Koivunen P, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483, 484-488 (2012).
8. Levental K. R, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891-906 (2009).
9. Mouw J. K, et al. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat. Med. 20, 360-367 (2014).
10. Kumar S, & Weaver V. M. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 28, 113-127 (2009).
11. Lopez J. I, Kang I, You W.-K, McDonald D. M, & Weaver V. M. In situ force mapping of mammary gland transformation. Integr. Biol. (Camb) 3, 910-921 (2011).
12. Geiss G. K, et al. Direct multiplexed measurement of gene expression with colorcoded probe pairs. Nat. Biotechnol. 26, 317-325 (2008).
13. Colman H, et al. A multigene predictor of outcome in glioblastoma. Neuro-Oncol. 12, 49-57 (2010).
14. Ruoslahti E. Brain extracellular matrix. Glycobiology 6, 489-492 (1996).
15. Wade A, et al. Proteoglycans and their roles in brain cancer. FEBS J. 280, 2399-2417 (2013).
16. Zimmermann D. R, & Dours-Zimmermann M. T. Extracellular matrix of the central nervous system: from neglect to challenge. Histochem. Cell Biol. 130, 635-653 (2008).
17. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
18. Brennan C. W, et al. The somatic genomic landscape of glioblastoma. Cell 155, 462-477 (2013).
19. Masson N, & Ratcliffe P. J. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab. 2, 3 (2014).
20. Koperek O, Akin E, Asari R, Niederle B, & Neuhold N. Expression of hypoxiainducible factor 1 in papillary thyroid carcinoma is associated with desmoplastic stromal reaction and lymph node metastasis. Virchows Arch. 463, 795-802 (2013).
21. Midwood K. S, & Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J. Cell Commun. Signal. 3, 287-310 (2009).
22. Turcan S, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479-483 (2012).
23. Chesnelong C, et al. Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro-Oncol. 16, 686-695 (2014).
24. Tarhonskaya H, et al. Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. Nat. Commun. 5, 3423 (2014).
25. Wierenga A. T. J, Vellenga E, & Schuringa J. J. Convergence of hypoxia and TGF pathways on cell cycle regulation in human hematopoietic stem/progenitor cells. PLoS ONE 9, e93494 (2014).
26. Marucci G, et al. Pathological spectrum in recurrences of glioblastoma multiforme. Pathologica 107, 1-8 (2015).
27. Li R, et al. Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. Oncotarget 6, 7318-7324 (2015).
28. Barcellos-Hoff M. H, & Ravani S. A. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60, 1254-1260 (2000).
29. Paszek M. J, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 8, 241-254 (2005).
30. Miroshnikova Y. A, et al. Engineering strategies to recapitulate epithelial morphogenesis within synthetic three-dimensional extracellular matrix with tunable mechanical properties. Phys. Biol. 8, 026013 (2011).
31. Chappell W. H, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2, 135-164 (2011).
32. Chang J. H, et al. MicroRNA-203 modulates the radiation sensitivity of human malignant glioma cells. Int. J. Radiat. Oncol. Biol. Phys. 94, 412-420 (2016).
33. Liao H, et al. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget 6, 8914-8928 (2015).
34. Le L. T.-N, et al. Loss of miR-203 regulates cell shape and matrix adhesion through ROBO1/Rac/FAK in response to stiffness. J. Cell Biol. 212, 707-719 (2016).
35. Scherr M, et al. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res. 35, e149 (2007).
36. Williams S. C, et al. R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1 upregulation in adult glioma. Acta Neuropathol. 121, 279-281 (2011).
37. Xu W, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17-30 (2011).
38. Noushmehr H, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522 (2010).
39. Evans S. M, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin. Cancer Res. 10, 8177-8184 (2004).
40. Vordermark D. Significance of hypoxia in malignant glioma. Re: Evans et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177-84. Clin. Cancer Res. 11, 3966-3967 (2005); Evans S. M, et al. response 3967-3968.
41. Lu K. V, et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22, 21-35 (2012).
42. Johnson K. R, Leight J. L, & Weaver V. M. Demystifying the effects of a threedimensional microenvironment in tissue morphogenesis. Methods Cell Biol. 83, 547-583 (2007).
43. Sarkaria J. N, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res. 12, 2264-2271 (2006).
44. Turcan S, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget 4, 1729-1736 (2013).
45. Kriegel A. J, & Liang M. MicroRNA in situ hybridization for formalin fixed kidney tissues. J. Vis. Exp. 81, 50785 (2013).
46. Lakins J. N, Chin A. R, & Weaver V. M. Exploring the link between human embryonic stem cell organization and fate using tension-calibrated extracellular matrix functionalized polyacrylamide gels. Methods Mol. Biol. 916, 317-350 (2012).